Vor Biopharma Inc.
VOR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | $0 | $0 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $14 | $261 | $27 | $25 |
| G&A Expenses | $14 | $2 | $7 | $0 |
| SG&A Expenses | $14 | $2 | $7 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $10 | $0 | $0 |
| Operating Expenses | $28 | $274 | $33 | $30 |
| Operating Income | -$28 | -$274 | -$33 | -$31 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$785 | -$1,299 | $1 | $1 |
| Pre-Tax Income | -$813 | -$1,574 | -$32 | -$31 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$813 | -$1,574 | -$32 | -$31 |
| % Margin | – | – | – | – |
| EPS | -121.63 | -251.2 | -5.2 | -9 |
| % Growth | 51.6% | -4,730.8% | 42.2% | – |
| EPS Diluted | -121.63 | -251.2 | -5.2 | -9 |
| Weighted Avg Shares Out | 7 | 6 | 6 | 3 |
| Weighted Avg Shares Out Dil | 7 | 6 | 6 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $2 | $1 | $1 |
| EBITDA | -$813 | -$242 | -$32 | -$30 |
| % Margin | – | – | – | – |